DOCSLIB.ORG

G Protein-Coupled Receptors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
G Protein-Coupled Receptors Alexander, S. P. H., Christopoulos, A., Davenport, A. P., Kelly, E., Marrion, N. V., Peters, J. A., ... CGTP Collaborators (2017). THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled receptors. British Journal of Pharmacology, 174, S17-S129. https://doi.org/10.1111/bph.13878 Publisher's PDF, also known as Version of record License (if available): CC BY Link to published version (if available): 10.1111/bph.13878 Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via Wiley at https://doi.org/10.1111/bph.13878 . Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/pure/about/ebr-terms S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2017/18: G protein-coupled receptors. British Journal of Pharmacology (2017) 174, S17–S129 THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled receptors Stephen PH Alexander1, Arthur Christopoulos2, Anthony P Davenport3, Eamonn Kelly4, Neil V Marrion4, John A Peters5, Elena Faccenda6, Simon D Harding6,AdamJPawson6, Joanna L Sharman6, Christopher Southan6, Jamie A Davies6 and CGTP Collaborators 1 School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2 Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria 3052, Australia 3 Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK 4 School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 5 Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 6 Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2017/18 provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point-in-time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.13878/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid-2017, and supersedes data presented in the 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature Committee of the Union of Basic and Clinical Pharmacology (NC-IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate. Conflict of interest The authors state that there are no conflicts of interest to declare. © 2017 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. Overview: G protein-coupled receptors (GPCRs) are the largest class of membrane proteins in the human genome. The term "7TM receptor" is commonly used interchangeably with "GPCR", although there are some receptors with seven transmembrane domains that do not signal through G proteins. GPCRs share a common architecture, each consisting of a single polypeptide with an extracellular N-terminus, an intracellular C-terminus and seven hydrophobic transmembrane domains (TM1-TM7) linked by three extracellular loops (ECL1-ECL3) and three intracellular loops (ICL1-ICL3). About 800 GPCRs have been identified in man, of which about half have sensory functions, mediating olfaction (∼400), taste (33), light perception (10) and pheromone signalling (5) [1362]. The remaining ∼350 non-sensory GPCRs mediate signalling by ligands that range in size from small molecules to peptides to large proteins; they are the targets for the majority of drugs in clinical usage [1519, 1631], although only a minority of these receptors are exploited therapeutically. The first classification scheme to be proposed for GPCRs [1030] divided them, on the basic of sequence homology, into six classes. These classes and their prototype members were as follows: Class A (rhodopsin-like), Class B (secretin receptor family), Class C (metabotropic glutamate), Class D (fungal mating pheromone receptors), Class E (cyclic AMP receptors) and Class F (frizzled/smoothened). Of these, classes D and E are not found in vertebrates. An alternative classification scheme "GRAFS" [1737] divides vertebrate GPCRs into five classes, overlapping with the A-F nomenclature, viz: Searchable database: http://www.guidetopharmacology.org/index.jsp G protein-coupled receptors S17 Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13878/full S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2017/18: G protein-coupled receptors. British Journal of Pharmacology (2017) 174, S17–S129 Glutamate family (class C), which includes metabotropic glutamate receptors, a calcium-sensing receptor and GABAB receptors, as well as three taste type 1 receptors and a family of pheromone receptors (V2 receptors) that are abundant in rodents but absent in man [1362]. Rhodopsin family (class A), which includes receptors for a wide variety of small molecules, neurotransmitters, peptides and hormones, together with olfactory receptors, visual pigments, taste type 2 receptors and five pheromone receptors (V1 receptors). Adhesion family GPCRs are phylogenetically related to class B receptors, from which they differ by possessing large extracellular N-termini that are autoproteolytically cleaved from their 7TM domains at a conserved "GPCR proteolysis site" (GPS) which lies within a much larger (˜320 residue) "GPCR autoproteolysis-inducing" (GAIN) domain, an evolutionary ancient mofif also found in polycystic kidney disease 1 (PKD1)-like proteins, which has been suggested to be both required and sufficient for autoproteolysis [1609]. Frizzled family consists of 10 Frizzled proteins (FZD(1-10)) and Smoothened (SMO). The FZDs are activated by secreted lipoglycoproteins of the WNT family, whereas SMO is indirectly activated by the Hedgehog (HH) family of proteins acting on the transmembrane protein Patched (PTCH). Secretin family (class B), encoded by 15 genes in humans. The ligands for receptors in this family are polypeptide hormones of 27-141 amino acid residues; nine of the mammalian receptors respond to ligands that are structurally related to one another (glucagon, glucagon-like peptides (GLP-1, GLP-2), glucose-dependent insulinotropic polypeptide (GIP), secretin, vasoactive intestinal peptide (VIP), pituitary adenylate cyclase-activating polypeptide (PACAP) and growth-hormone-releasing hormone (GHRH)) [738]. GPCR families Family Class A Class B (Secretin) Class C (Glutamate) Adhesion Frizzled Receptors with known ligands 197 15 12 0 11 Orphans 87 (54)a - 8 (1)a 26 (6)a 0 Sensory (olfaction) 390b,c -- -- Sensory (vision) 10d opsins - - - - Sensory (taste) 30c taste 2 - 3c taste 1 - - Sensory (pheromone) 5c vomeronasal 1 - - - - Total 719 15 22 33 11 aNumbers in brackets refer to orphan receptors for which an endogenous ligand has been proposed in at least one publication, see [414]; b[1511]; c[1362]; d[1941]. β Much of our current understanding of the structure and function of GPCRs is the result of pioneering work on the visual pigment rhodopsin and on the 2 adrenoceptor, the latter culminating in the award of the 2012 Nobel Prize in chemistry to Robert Lefkowitz and Brian Kobilka [1021, 1137]. Family structure S19 Orphan and other 7TM receptors S50 Calcium-sensing receptor S73 Gonadotrophin-releasing hormone receptors S19 Class A Orphans S51 Cannabinoid receptors S74 GPR18, GPR55 and GPR119 – Class B Orphans S52 Chemerin receptor S76 Histamine receptors S28 Class C Orphans S52 Chemokine receptors S77 Hydroxycarboxylic acid receptors S28 Taste 1 receptors S57 Cholecystokinin receptors S78 Kisspeptin receptor S29 Taste 2 receptors S58 Class Frizzled GPCRs S79 Leukotriene receptors S30 Other 7TM proteins S59 Complement peptide receptors S80 Lysophospholipid (LPA) receptors S30 5-Hydroxytryptamine receptors S60 Corticotropin-releasing factor receptors S82 Lysophospholipid (S1P) receptors S34 Acetylcholine receptors (muscarinic) S61 Dopamine receptors S83 Melanin-concentrating hormone
Load more

Recommended publications
  • Chimeric Gpcrs Mimic Distinct Signaling Pathways and Modulate Microglia Responses
    bioRxiv preprint doi: https://doi.org/10.1101/2021.06.21.449162; this version posted June 21, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Chimeric GPCRs mimic distinct signaling pathways and modulate microglia responses Rouven Schulz, Medina Korkut-Demirbaş, Gloria Colombo, Sandra Siegert† Author affiliation: Institute of Science and Technology (IST) Austria, Am Campus 1, 3400 Klosterneuburg, Austria † Corresponding author: [email protected] Keywords: G protein coupled receptor (GPCR), DREADD, β2-adrenergic receptor (β2AR/ADRB2), microglia, inflammation, GPR65, GPR109A/HCAR2 Abstract G protein-coupled receptors (GPCRs) regulate multiple processes ranging from cell growth and immune responses to neuronal signal transmission. However, ligands for many GPCRs remain unknown, suffer from off-target effects or have poor bioavailability. Additional challenges exist to dissect cell type-specific responses when the same GPCR is expressed on different cells within the body. Here, we overcome these limitations by engineering DREADD-based GPCR chimeras that selectively bind their agonist clozapine-N-oxide (CNO) and mimic a GPCR-of-interest. We show that the chimeric DREADD-β2-adrenergic receptor (β2AR/ADRB2) triggers comparable responses to levalbuterol on second messenger and kinase activity, post-translational modifications, and protein-protein interactions. Moreover, we successfully recapitulate β2AR-mediated filopodia formation in microglia, a β2AR-expressing immune cell that can drive inflammation in the nervous system. To further dissect microglial inflammation, we compared DREADD-β2AR with two additionally designed DREADD-based chimeras mimicking GPR65 and GPR109A/HCAR2, both enriched in microglia.
    [Show full text]
  • The Orphan Receptor GPR17 Is Unresponsive to Uracil Nucleotides and Cysteinyl Leukotrienes S
    Supplemental material to this article can be found at: http://molpharm.aspetjournals.org/content/suppl/2017/03/02/mol.116.107904.DC1 1521-0111/91/5/518–532$25.00 https://doi.org/10.1124/mol.116.107904 MOLECULAR PHARMACOLOGY Mol Pharmacol 91:518–532, May 2017 Copyright ª 2017 by The American Society for Pharmacology and Experimental Therapeutics The Orphan Receptor GPR17 Is Unresponsive to Uracil Nucleotides and Cysteinyl Leukotrienes s Katharina Simon, Nicole Merten, Ralf Schröder, Stephanie Hennen, Philip Preis, Nina-Katharina Schmitt, Lucas Peters, Ramona Schrage,1 Celine Vermeiren, Michel Gillard, Klaus Mohr, Jesus Gomeza, and Evi Kostenis Molecular, Cellular and Pharmacobiology Section, Institute of Pharmaceutical Biology (K.S., N.M., Ral.S., S.H., P.P., N.-K.S, L.P., J.G., E.K.), Research Training Group 1873 (K.S., E.K.), Pharmacology and Toxicology Section, Institute of Pharmacy (Ram.S., K.M.), University of Bonn, Bonn, Germany; UCB Pharma, CNS Research, Braine l’Alleud, Belgium (C.V., M.G.). Downloaded from Received December 16, 2016; accepted March 1, 2017 ABSTRACT Pairing orphan G protein–coupled receptors (GPCRs) with their using eight distinct functional assay platforms based on label- cognate endogenous ligands is expected to have a major im- free pathway-unbiased biosensor technologies, as well as molpharm.aspetjournals.org pact on our understanding of GPCR biology. It follows that the canonical second-messenger or biochemical assays. Appraisal reproducibility of orphan receptor ligand pairs should be of of GPR17 activity can be accomplished with neither the coapplica- fundamental importance to guide meaningful investigations into tion of both ligand classes nor the exogenous transfection of partner the pharmacology and function of individual receptors.
    [Show full text]
  • Genome-Wide Prediction of Small Molecule Binding to Remote
    bioRxiv preprint doi: https://doi.org/10.1101/2020.08.04.236729; this version posted August 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Genome-wide Prediction of Small Molecule Binding 2 to Remote Orphan Proteins Using Distilled Sequence 3 Alignment Embedding 1 2 3 4 4 Tian Cai , Hansaim Lim , Kyra Alyssa Abbu , Yue Qiu , 5,6 1,2,3,4,7,* 5 Ruth Nussinov , and Lei Xie 1 6 Ph.D. Program in Computer Science, The Graduate Center, The City University of New York, New York, 10016, USA 2 7 Ph.D. Program in Biochemistry, The Graduate Center, The City University of New York, New York, 10016, USA 3 8 Department of Computer Science, Hunter College, The City University of New York, New York, 10065, USA 4 9 Ph.D. Program in Biology, The Graduate Center, The City University of New York, New York, 10016, USA 5 10 Computational Structural Biology Section, Basic Science Program, Frederick National Laboratory for Cancer Research, 11 Frederick, MD 21702, USA 6 12 Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel 13 Aviv, Israel 7 14 Helen and Robert Appel Alzheimer’s Disease Research Institute, Feil Family Brain & Mind Research Institute, Weill 15 Cornell Medicine, Cornell University, New York, 10021, USA * 16 [email protected] 17 July 27, 2020 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.08.04.236729; this version posted August 5, 2020.
    [Show full text]
  • Edinburgh Research Explorer
    Edinburgh Research Explorer International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list Citation for published version: Davenport, AP, Alexander, SPH, Sharman, JL, Pawson, AJ, Benson, HE, Monaghan, AE, Liew, WC, Mpamhanga, CP, Bonner, TI, Neubig, RR, Pin, JP, Spedding, M & Harmar, AJ 2013, 'International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands', Pharmacological reviews, vol. 65, no. 3, pp. 967-86. https://doi.org/10.1124/pr.112.007179 Digital Object Identifier (DOI): 10.1124/pr.112.007179 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: Pharmacological reviews Publisher Rights Statement: U.S. Government work not protected by U.S. copyright General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 02. Oct. 2021 1521-0081/65/3/967–986$25.00 http://dx.doi.org/10.1124/pr.112.007179 PHARMACOLOGICAL REVIEWS Pharmacol Rev 65:967–986, July 2013 U.S.
    [Show full text]
  • Emerging Pharmacological Strategies for the Treatment
    Emerging pharmacological strategies for the treatment of fibromyalgia LAWSON, Kim Available from Sheffield Hallam University Research Archive (SHURA) at: http://shura.shu.ac.uk/15300/ This document is the author deposited version. You are advised to consult the publisher's version if you wish to cite from it. Published version LAWSON, Kim (2017). Emerging pharmacological strategies for the treatment of fibromyalgia. World Journal of Pharmacology, 6 (1), 1-10. Repository use policy Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in SHURA to facilitate their private study or for non- commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain. Sheffield Hallam University Research Archive http://shura.shu.ac.uk World Journal of WJ P Pharmacology Submit a Manuscript: http://www.wjgnet.com/esps/ World J Pharmacol 207 March 9; 6(): -0 DOI: 0.5497/wjp.v6.i. ISSN 2220-392 (online) MINIREVIEWS Emerging pharmacological strategies for the treatment of ibromyalgia Kim Lawson Kim Lawson, Department of Biosciences and Chemistry, Bio­ presenting with a complex of symptoms dominated by molecular Sciences Research Centre, Shefield Hallam University, chronic widespread pain associated with the existence of a Faculty of Health and Wellbeing, Sheffield S1 1WB, United range of co-morbidities, such as fatigue, sleep disturbance, Kingdom cognitive impairment, anxiety and depression. Current treatments include drugs that target serotonin and nor- Author contributions: Lawson K researched the materials for the article and wrote the manuscript.
    [Show full text]
  • The Roles Played by Highly Truncated Splice Variants of G Protein-Coupled Receptors Helen Wise
    Wise Journal of Molecular Signaling 2012, 7:13 http://www.jmolecularsignaling.com/content/7/1/13 REVIEW Open Access The roles played by highly truncated splice variants of G protein-coupled receptors Helen Wise Abstract Alternative splicing of G protein-coupled receptor (GPCR) genes greatly increases the total number of receptor isoforms which may be expressed in a cell-dependent and time-dependent manner. This increased diversity of cell signaling options caused by the generation of splice variants is further enhanced by receptor dimerization. When alternative splicing generates highly truncated GPCRs with less than seven transmembrane (TM) domains, the predominant effect in vitro is that of a dominant-negative mutation associated with the retention of the wild-type receptor in the endoplasmic reticulum (ER). For constitutively active (agonist-independent) GPCRs, their attenuated expression on the cell surface, and consequent decreased basal activity due to the dominant-negative effect of truncated splice variants, has pathological consequences. Truncated splice variants may conversely offer protection from disease when expression of co-receptors for binding of infectious agents to cells is attenuated due to ER retention of the wild-type co-receptor. In this review, we will see that GPCRs retained in the ER can still be functionally active but also that highly truncated GPCRs may also be functionally active. Although rare, some truncated splice variants still bind ligand and activate cell signaling responses. More importantly, by forming heterodimers with full-length GPCRs, some truncated splice variants also provide opportunities to generate receptor complexes with unique pharmacological properties. So, instead of assuming that highly truncated GPCRs are associated with faulty transcription processes, it is time to reassess their potential benefit to the host organism.
    [Show full text]
  • G-Protein-Coupled Receptor Gpr17 Regulates Oligodendrocyte
    www.nature.com/scientificreports OPEN G-Protein-Coupled Receptor Gpr17 Regulates Oligodendrocyte Diferentiation in Response Received: 11 May 2017 Accepted: 2 October 2017 to Lysolecithin-Induced Published: xx xx xxxx Demyelination Changqing Lu1,2, Lihua Dong2, Hui Zhou3, Qianmei Li3, Guojiao Huang3, Shu jun Bai3 & Linchuan Liao1 Oligodendrocytes are the myelin-producing cells of the central nervous system (CNS). A variety of brain disorders from “classical” demyelinating diseases, such as multiple sclerosis, stroke, schizophrenia, depression, Down syndrome and autism, are shown myelination defects. Oligodendrocyte myelination is regulated by a complex interplay of intrinsic, epigenetic and extrinsic factors. Gpr17 (G protein- coupled receptor 17) is a G protein-coupled receptor, and has been identifed to be a regulator for oligodendrocyte development. Here, we demonstrate that the absence of Gpr17 enhances remyelination in vivo with a toxin-induced model whereby focal demyelinated lesions are generated in spinal cord white matter of adult mice by localized injection of LPC(L-a-lysophosphatidylcholine). The increased expression of the activated form of Erk1/2 (phospho-Erk1/2) in lesion areas suggested the potential role of Erk1/2 activity on the Gpr17-dependent modulation of myelination. The absence of Gpr17 enhances remyelination is correlate with the activated Erk1/2 (phospho-Erk1/2).Being a membrane receptor, Gpr17 represents an ideal druggable target to be exploited for innovative regenerative approaches to acute and chronic CNS diseases. Oligodendrocytes are the myelin-producing cells of the central nervous system (CNS), and as such, wrap layers of lipid-dense insulating myelin around axons1. Mature oligodendrocytes have also been shown to provide met- abolic support to axons through transport systems within myelin, which may help prevent neurodegeneration2.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • GABAB Receptors and Pain
    King’s Research Portal DOI: 10.1016/j.neuropharm.2017.05.012 Document Version Peer reviewed version Link to publication record in King's Research Portal Citation for published version (APA): Malcangio, M. (2017). GABAB receptors and pain. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2017.05.012 Citing this paper Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections. General rights Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights. •Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research. •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim.
    [Show full text]
  • Functioning of the Dimeric GABAB Receptor Extracellular Domain Revealed by Glycan Wedge Scanning
    Functioning of the dimeric GABAB receptor extracellular domain revealed by glycan wedge scanning Philippe Rondard1§, Siluo Huang2§, Carine Monnier1, Haijun Tu2, Bertrand Blanchard1, Nadia Oueslati1, Fanny Malhaire1, Ying Li2, Eric Trinquet3, Gilles Labesse4,5, Jean-Philippe Pin1 & Jianfeng Liu2 1 CNRS, UMR 5203, Institut de Génomique Fonctionnelle, Montpellier, France and INSERM, U661, Montpellier, France and Université Montpellier 1,2, Montpellier F-34000, France. 2, Sino-France Laboratory for Drug Screening, Key Laboratory of Molecular Biophysics of Ministry of Education, Huazhong University of Science and Technology, Wuhan, Hubei, China 3 CisBio International, Parc technologique Marcel Boiteux, Bagnols/Cèze cedex F-30204, France 4, Centre de Biochimie Structurale, CNRS UMR5048, Université Montpellier 1, Montpellier F-34060, France 5 INSERM U414, Montpellier, F-34094 France § P.R. and S.H. contributed equally to this work Correspondence should be addressed to J.P.P ([email protected]) and J.L. ([email protected]). Running title : Functional analysis of GABAB receptor VFTs using N-glycans Total character count (including spaces) : 55,058 1 Abstract The G-protein coupled receptor activated by the neurotransmitter GABA is made up of two subunits, GABAB1 and GABAB2. While GABAB1 binds agonists, GABAB2 is required for trafficking GABAB1 to the cell surface, increasing agonist affinity to GABAB1, and activating associated G-proteins. These subunits each comprise two domains, a Venus flytrap (VFT) domain and a heptahelical (7TM) domain. How agonist binding to the GABAB1 VFT leads to GABAB2 7TM activation remains unknown. Here, we used a glycan wedge scanning approach to investigate how the GABAB VFT dimer controls receptor activity.
    [Show full text]
  • Durham E-Theses
    Durham E-Theses Elemental Fluorine for the Greener Synthesis of Life-Science Building Blocks HARSANYI, ANTAL How to cite: HARSANYI, ANTAL (2016) Elemental Fluorine for the Greener Synthesis of Life-Science Building Blocks, Durham theses, Durham University. Available at Durham E-Theses Online: http://etheses.dur.ac.uk/11705/ Use policy The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for personal research or study, educational, or not-for-prot purposes provided that: • a full bibliographic reference is made to the original source • a link is made to the metadata record in Durham E-Theses • the full-text is not changed in any way The full-text must not be sold in any format or medium without the formal permission of the copyright holders. Please consult the full Durham E-Theses policy for further details. Academic Support Oce, Durham University, University Oce, Old Elvet, Durham DH1 3HP e-mail: [email protected] Tel: +44 0191 334 6107 http://etheses.dur.ac.uk 2 Durham University A thesis entitled Elemental Fluorine for the Greener Synthesis of Life-Science Building Blocks by Antal Harsanyi (College of St. Hild and St. Bede) A candidate for the degree of Doctor of Philosophy Department of Chemistry, Durham University 2016 Antal Harsanyi: Elemental fluorine for the greener synthesis of life-science building blocks Abstract Fluorinated organic compounds are increasingly important in many areas of our modern lives, especially in pharmaceutical and agrochemical applications where the incorporation of this element can have a major influence on biochemical properties.
    [Show full text]
  • Identification of Gene Expression and DNA Methylation of SERPINA5 and TIMP1 As Novel Prognostic Markers in Lower-Grade Gliomas
    Identification of gene expression and DNA methylation of SERPINA5 and TIMP1 as novel prognostic markers in lower-grade gliomas Wen-Jing Zeng1,2,3,4, Yong-Long Yang5, Zhi-Peng Wen1,2, Peng Chen1,2, Xiao-Ping Chen1,2 and Zhi-Cheng Gong3,4 1 Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan, China 2 Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, Hunan, China 3 Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China 4 National Clinical Research Center for Geriatric Disorders (XIANGYA), Xiangya Hospital, Central South University, Changsha, Hunan, China 5 Department of Clinical Pharmacology Research Center, Changsha Carnation Geriatrics Hospital, Changsha, Hunan, China ABSTRACT Background. Lower-grade gliomas (LGGs) is characteristic with great difference in prognosis. Due to limited prognostic biomarkers, it is urgent to identify more molecular markers to provide a more objective and accurate tumor classification system for LGGs. Methods. In the current study, we performed an integrated analysis of gene expression data and genome-wide methylation data to determine novel prognostic genes and methylation sites in LGGs. Results. To determine genes that differentially expressed between 44 short-term survivors (<2 years) and 48 long-term survivors (≥2 years), we searched LGGs TCGA RNA-seq dataset and identified 106 differentially expressed genes. SERPINA5 and Submitted 11 October 2019 Accepted 9 May 2020 TIMP1 were selected for further study. Kaplan–Meier plots showed that SERPINA5 Published 3 June 2020 and TIMP1 expression were significantly correlated with overall survival (OS) and Corresponding authors relapse-free survival (RFS) in TCGA LGGs patients.
    [Show full text]